Tech Company Financing Transactions

Avidity Biosciences Funding Round

Avidity Biosciences secured a $100 million Series C funding round on 11/14/2019. Investors included RTW Investments, Alethea Capital and Alexandria Venture Investments.

Transaction Overview

Company Name
Avidity Biosciences
Announced On
11/14/2019
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series C
Investors

RTW Investments (Lead Investor) (Roderick Wong)

Alethea Capital

Alexandria Venture Investments

Boxer Capital

Brace Pharma (Todd Brady)

Cormorant Asset Management

CureDuchenne Ventures (Debra Miller)

EcoR1 Capital Management

Logos Capital

Partner Fund Management

Perceptive Advisors

Takeda Ventures (Michael Martin)

Proceeds Purpose
These funds will enable Avidity to advance our growing proprietary portfolio of multiple programs, including our AOC treatment of myotonic dystrophy type I, to treat serious muscle disorders.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
10975 North Torrey Pines Rd. 150
La Jolla, CA 92037
USA
Phone
(858) 401-7900
Website
www.aviditybiosciences.com
Email Address
[email protected]
Overview
Avidity Biosciences LLC offers research, development, and manufacturing of drug candidates which include antibody-siRNA complexes.
Profile
Avidity Biosciences LinkedIn Company Profile
Social Media
Avidity Biosciences Company Twitter Account
Company News
Avidity Biosciences News
Facebook
Avidity Biosciences on Facebook
YouTube
Avidity Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chairman
Troy Wilson
  Troy Wilson LinkedIn Profile  Troy Wilson Twitter Account  Troy Wilson News  Troy Wilson on Facebook
Chief Executive Officer
Sarah Boyce
  Sarah Boyce LinkedIn Profile  Sarah Boyce Twitter Account  Sarah Boyce News  Sarah Boyce on Facebook
Chief Scientific Officer
Arthur Levin
  Arthur Levin LinkedIn Profile  Arthur Levin Twitter Account  Arthur Levin News  Arthur Levin on Facebook
Vice President
Andrew Geall
  Andrew Geall LinkedIn Profile  Andrew Geall Twitter Account  Andrew Geall News  Andrew Geall on Facebook
Vice President
John Wallen
  John Wallen LinkedIn Profile  John Wallen Twitter Account  John Wallen News  John Wallen on Facebook
VP - Bus. Development
Kent Hawryluk
  Kent Hawryluk LinkedIn Profile  Kent Hawryluk Twitter Account  Kent Hawryluk News  Kent Hawryluk on Facebook
VP - Finance
Vanessa Jacoby
  Vanessa Jacoby LinkedIn Profile  Vanessa Jacoby Twitter Account  Vanessa Jacoby News  Vanessa Jacoby on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/14/2019: Guild Education venture capital transaction
Next: 11/14/2019: Risalto Health venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.